Tag Archives: Forbes

Valeant CEO tries to paint happy face on 4Q results; markets not buying the turnaround–yet?

The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Humana bails Obamacare exchanges; signals beginning of the end of private insurer involvement

The News: Humana Inc. (Louisville KY) said it will leave the commercial individual insurance business effective in 2018, including coverage offered on public exchanges under the Affordable Care Act, after being unable to… Read more »

Walgreens cuts offer for Rite Aid, casting doubt on merger; analysts say deal still alive

The News: Walgreens Boots Alliance (Deerfield IL) on Monday (January 30, 2017) entered into a new agreement with Rite Aid (Camp Hill PA) to buy the drugstore chain for at least $2 less per share… Read more »

Mallinckrodt will pay $100 million to settle drug antitrust (price-gouging) charges; why competition, not fines, is the only antidote

The News: Irish drugmaker Mallinckrodt PLC (Dublin) and a US subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for… Read more »

UnitedHealth registers strong 2016 finish; foresaw Trumpcare downside, potential, early on

With conjecture churning about how Republicans might replace the federal health law, the CEO of UnitedHealth Group Inc. (Minnetonka MN) offered no specifics Tuesday (January 17, 2017) but said he… Read more »

Drugs that may shape 2017 and the trends molding new-drug discovery

Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Obamacare repeal rushed forward by GOP; realistically, what can we expect next?

House Republicans on Friday (January 13, 2017) took the first step in repealing President Obama’s signature healthcare law with a 227 to 198 vote on a budget resolution passed earlier… Read more »

Valeant divests assets worth $2.1 billion to ease debt load; finally a smart move, but too little, too late?

Valeant Pharmaceuticals International Inc. (Laval Quebec) is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than… Read more »

Biotech predictions for 2017 return to positive fundamentals; 2016 meltdown still in rear-view mirror

The NASDAQ Biotech Index got hammered in 2016–-but mostly due to the market melting in January 2016. The Nasdaq Biotech Index collapsed 28% in the opening weeks of 2016 and… Read more »